单独的内血管治疗与慢性肢体威胁性缺血症患者的内血管治疗加风病 - 多中心比较研究
Takahiro Tokuda1, Naoki Yoshioka2, Akiko Tanaka3
1Department of Cardiology, Nagoya Heart Center Nagoya Japan.
Circulation reports
|February 11, 2026
概括
在内血管治疗 (EVT) 后,Rheocarna®显著改善了慢性肢体威胁性缺血症 (CLTI) 和小动脉疾病 (SAD2) 的患者的伤口愈合. 这表明Rheocarna可能有利于接受EVT的特定CLTI患者.
科学领域:
- 血管外科 血管外科
- 再生医学是一种再生医学.
- 临床研究 临床研究
背景情况:
- 慢性四肢威胁性缺血症 (CLTI) 是一个重大的临床挑战.
- 内血管治疗 (EVT) 是针对下病变的常见干预措施.
- 评估辅助疗法以改善EVT后的结果至关重要.
研究的目的:
- 评估Rheocarna®作为CLTI患者在EVT后的辅助疗法的影响.
- 为了比较单独的EVT和EVT与Rheocarna®之间的伤口愈合率和其他临床结果.
- 为了确定可能从Rheocarna®中受益最多的患者子组.
主要方法:
- 对913名CLTI患者进行EVT以检查下内病变的回顾性分析.
- 患者分组为单独使用EVT或EVT与Rheocarna®.
- 倾向分数匹配 (PSM) 用于控制基线差异;分析了88对匹配对.
- 主要结局:一年内伤口愈合率;次要结局:愈合时间,截肢,重新干预.
主要成果:
- 在患有小动脉疾病 (SAD2) 的患者中,EVT加Rheocarna®组与单独EVT (26.0%;P=0.01) 相比,显示出明显更高的1年伤口愈合率 (66.6%).
- 没有观察到群体之间在伤口愈合时间,重大截肢率或1年后重新干预率方面存在显著差异.
- 在88个匹配对之间,PSM成功地平衡了基线特征.
结论:
- 附加的Rheocarna®疗法显著改善了经过EVT的SAD2的CLTI患者的1年伤口愈合率.
- 在这个队列中,Rheocarna®没有显著影响伤口愈合时间,重大截肢或重新干预率.
- 患有CLTI和SAD2的患者可能是EVT后Rheocarna®治疗的合适候选人.
相关概念视频
Open Angle Glaucoma: Treatment
1.0K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.0K
Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Parkinson's Disease: Treatment
1.2K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.2K
Alzheimer's Disease: Treatment
975
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
975
Anticholinesterase Agents: Poisoning and Treatment
1.7K
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
1.7K
Angle Closure Glaucoma: Treatment
1.3K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.3K


